1313363-54-0

Basic information

• Product Name: NVP-CGM097
• Synonyms: NVP-CGM097;CGM097;NVP-CGM097 (CGM097);(S)-1-(4-Chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-[methyl[4-(4-methyl-3-oxopiperazin-1-yl)-trans-cyclohexylmethyl]amino]phenyl)-1,4-dihydro-2H-isoquinolin-3-one;(S)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2-(4-(methyl(((1r,4r)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)methyl)amino)phenyl)-1,2-dihydroisoquinolin-3(4H)-one hydrochloride
• CAS NO: 1313363-54-0
• Molecular Formula: C₃₈H₄₇ClN₄O₄
• Molecular Weight: 659.25718
• Mol File: 1313363-54-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 830.1±65.0 °C(Predicted)
• Appearance: /
• Density: 1.210±0.06 g/cm3(Predicted)
• PKA: 8.31±0.20(Predicted)
• CAS DataBase Reference: NVP-CGM097(CAS DataBase Reference)
• NIST Chemistry Reference: NVP-CGM097(1313363-54-0)
• EPA Substance Registry System: NVP-CGM097(1313363-54-0)

Safety Data

• Hazardous Substances Data: 1313363-54-0(Hazardous Substances Data)

Usage

General Description

NVP-CGM097 is a potent and selective small molecule inhibitor of the protein kinase A, known as p70S6K, which regulates cell growth, survival, and proliferation. It functions by directly binding to and inhibiting the activity of p70S6K, thereby reducing the phosphorylation of its downstream targets. This inhibition leads to the suppression of cell cycle progression and the induction of cell death in various cancer cell lines. NVP-CGM097 has shown promising results in preclinical studies, with the potential to be developed as a targeted therapy for cancers driven by hyperactive p70S6K signaling. It has also demonstrated good oral bioavailability and tolerability in animal models, making it a strong candidate for further development as an anticancer agent.

Upstream product

• 14064-15-4 (4-chlorophenyl)trimethylstannane 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 304873-80-1 (4-formyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 540-37-4 p-aminoiodobenzene 
• 60563-13-5 ethyl homovanillate 
• 1256581-66-4 (4-isopropoxy-3-methoxy-phenyl)-acetic acid ethyl ester 
• 1313365-54-6 (2-formyl-4-isopropoxy-5-methoxy-phenyl)-acetic acid ethyl ester 
• 1313365-57-9 (S)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1313365-97-7 4-(4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-1-methyl-piperazin-2-one 
• 1313365-98-8 [[2-(tert-butoxycarbonyl-methyl-amino)-ethyl]-(4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-amino]-acetic acid methyl ester 
• 1313365-94-4 (4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexylamino)-acetic acid methyl ester 
• 1313365-62-6 (4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-carbamic acid tert-butyl ester 
• 1313365-58-0 {4-[(4-iodo-phenylamino)-methyl]-trans-cyclohexyl}-carbamic acid tert-butyl ester 
• 1313365-56-8 {2-[(S)-(4-chloro-phenyl)-((S)-2-methyl-propane-2-sulfinylamino)-methyl]-4-isopropoxy-5-methoxy-phenyl}-acetic acid ethyl ester 

Relevant articles and documents

A p53 - MDM2 binding inhibitor dihydroxy isoquinoline derivative synthesis method

The invention discloses a synthetic method for preparing a non-peptide p53-MDM2-binding inhibitor dyhydroxyl quinoline derivative. The method comprises the following steps of: carrying out reductive amination on a compound 1 and a compound 2 to obtain a compound 3; and carrying out substitution, oxidization, reductive amination and deprotection amidation reaction to prepare a compound I. The synthetic method adopts a brand-new synthesis route, is simple and convenient to operate, high in yield, good in safety, environmentally-friendly, low in cost, and beneficial for technical production. FORMULA as shown in the specification.

CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION

A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively.